Provided by Tiger Trade Technology Pte. Ltd.

Amylyx Pharmaceuticals

13.55
+0.08000.59%
Post-market: 13.550.00000.00%16:34 EDT
Volume:1.22M
Turnover:16.52M
Market Cap:1.50B
PE:-8.85
High:13.84
Open:13.44
Low:13.32
Close:13.47
52wk High:17.49
52wk Low:3.11
Shares:110.54M
Float Shares:65.45M
Volume Ratio:0.95
T/O Rate:1.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5305
EPS(LYR):-1.5305
ROE:-61.59%
ROA:-36.41%
PB:4.91
PE(LYR):-8.85

Loading ...

Amylyx selects AMX0318 as development candidate for PBH

TIPRANKS
·
Jan 08

Amylyx Pharmaceuticals Advances AMX0318 as Long-Acting GLP-1 Receptor Antagonist for Rare Diseases

Reuters
·
Jan 08

Amylyx Pharmaceuticals Announces Nomination of Amx0318 as a Novel, Long-Acting Glp-1 Receptor Antagonist Development Candidate, Identified in Collaboration With Gubra a/S

THOMSON REUTERS
·
Jan 08

Amylyx Pharmaceuticals Inc - Gubra to Receive Over $50 Mln in Milestones and Royalties

THOMSON REUTERS
·
Jan 08

Assessing Amylyx Pharmaceuticals (AMLX) Valuation After Insider Buying And AMX0114 Trial Progress

Simply Wall St.
·
Jan 05

Director Karen Firestone Acquires Common Shares of Amylyx Pharmaceuticals Inc

Reuters
·
Dec 24, 2025

Is Amylyx Pharmaceuticals (AMLX) Overvalued After Its 250% Year‑to‑Date Share Price Surge?

Simply Wall St.
·
Dec 10, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Omnicom, Albemarle, energy companies

Reuters
·
Dec 06, 2025

BUZZ-Amylyx rises after promising early-stage trial for ALS drug

Reuters
·
Dec 05, 2025

BRIEF-Amylyx Pharmaceuticals Announces New Safety And Tolerability Cohort 1 Data Of Amx0114

Reuters
·
Dec 05, 2025

Amylyx Reports Positive Early Safety Data for AMX0114 in ALS Phase 1 LUMINA Trial

Reuters
·
Dec 05, 2025

Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of Amx0114 in ALS From First-in-Human Lumina Trial

THOMSON REUTERS
·
Dec 05, 2025

Amylyx Pharmaceuticals Inc - Amx0114 Well-Tolerated With No Serious Adverse Events

THOMSON REUTERS
·
Dec 05, 2025

Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian Reports Disposal of Common Shares

Reuters
·
Dec 04, 2025

Amylyx Pharmaceuticals Q3 EPS USD -0.37 Vs. IBES Estimate USD -0.47

Reuters
·
Nov 20, 2025

Is Amylyx (AMLX) Reshaping Its Investment Case With Improved Losses and Avexitide’s Path to Market?

Simply Wall St.
·
Nov 14, 2025

Stock Track | Amylyx Pharmaceuticals Soars Nearly 7% as Mizuho Boosts Price Target

Stock Track
·
Nov 10, 2025

Stock Track | Amylyx Pharmaceuticals Soars 5.61% Pre-Market as Mizuho Raises Target Price

Stock Track
·
Nov 10, 2025

Stock Track | Amylyx Pharmaceuticals Surges 5.61% Pre-Market on Mizuho's Target Price Hike

Stock Track
·
Nov 10, 2025

Assessing Amylyx Pharmaceuticals (AMLX) Valuation Following Recent Share Price Momentum

Simply Wall St.
·
Nov 09, 2025